The Picotti laboratory is interested in how protein conformational changes, such as those associated with protein aggregation or allostery, impact cellular physiology and result in human disease. They develop mass spectrometry-based structural and chemical proteomic methods aimed at monitoring protein conformational changes in the complex cellular milieu. The lab combines these tools with classical biochemical, cell biological, and genetic approaches in several lines of research.
Professor Küster conducts research in the field of chemical and functional proteomics. This research focuses on a range of questions relating to how proteins interact with each other and with active pharmaceutical ingredients, which molecular mechanisms play a role in cancer and how these can be used for individual approaches to clinical treatment. He uses chemical and biochemical methods as well as spectrometric and bioinformatic high throughput technologies.
After studying chemistry at the University of Cologne, Professor Küster obtained his doctorate in biochemistry at the University of Oxford. He subsequently worked as a postdoctoral researcher in Heidelberg, Germany, and Odense, Denmark. Prior to becoming a full professor at TUM and until 2007 he was Vice President of Cellzome AG, a Heidelberg-based biotech company. Professor Küster is the TUM Chair Proteomics and Bioanalytics and Vice Dean for Information Management of the TUM School of Life Sciences. His research is funded by numerous national, international and industry grants as well an ERC Advanced Grant. Professor Küster is one of the founders of the biotech company OmicScouts and the informatics start-up MSAID.
Helen J. Cooper is Professor of Mass Spectrometry and EPSRC Fellow in the School of Biosciences at the University of Birmingham. Her research focuses on developing mass spectrometry methods for in situ analysis of proteins. The aim is to combine ambient mass spectrometry, ion mobility spectrometry and native mass spectrometry to obtain spatial and structural information about proteins and their complexes directly from their physiological environment. She is a Director of the Rosalind Franklin Institute, and serves on the Editorial Boards of the Journal of the American Society for Mass Spectrometry and Analysis & Sensing. She is a Fellow of the Royal Society of Chemistry.
The circadian clock is an endogenous timing system that regulates, in a daily manner, physiological functions and behavior by modulating gene expression and protein function. Circadian control of transcription regulation is widely studied however the understanding of circadian dynamics in protein function is in its infancy. My work in the last years has pioneered the use of mass spectrometry-based quantitative proteomics to study temporal dynamics of protein abundance, cellular localization and post-transcriptional modifications (PTMs). My research group is using state of the art MS instrumentation to study circadian molecular mechanisms, from molecular to system levels, in normal conditions. In addition, we also investigate how circadian asynchrony and sleep disorders, a condition frequently associated with modern lifestyle, associate to metabolic, behavioral and cognitive disorders.
Hi! I’m Olly a Postdoctoral Researcher in the Department of Statistics, University of Oxford working with Charlotte Deane. I closely work with the Structural and Biophysical Science division at GSK headed by Chun-wa Chung. I am also a Todd-Bird Junior Research Fellow in Biochemistry at New College. My current work focuses on machine learning and statistical methodology for hydrogen-deuterium exchange mass spectrometry. I am particularly interested in accelerating the HDX pipeline and bridging the insights given by complementary biophysical techniques.
I was a graduate student on the Wellcome Trust Mathematical Genomics and Medicine PhD at Darwin College, Cambridge. I was supervised by Laurent Gatto, Paul DW Kirk and Kathryn Lilley working on Bayesian methodology for spatial Proteomics.
PhD 2007, Uppsala University. Group leader Cellzome, Heidelberg. Team leader and Head of Proteomics Core Facility at EMBL since 2016. Joint Appointment with the Structural and Computational Biology Unit.
Christoph Messner received his PhD in analytical chemistry at the University of Innsbruck. In 2016 he received a Wellcome Trust fellowship to study the origins of metabolism at the University of Cambridge. Since 2017 he has been a post-doctoral researcher in the laboratory of Markus Ralser at the Francis Crick Institute in London. His research has focused on the development of technologies and strategies for high-throughput proteomics. He has developed sample preparation and automation strategies as well as introduced LC-MS acquisition modes that allow the measurement of hundreds of proteomes per day. He has applied these technologies in several large-scale projects (with thousands of samples) ranging from systems biology, to clinical proteomics and drug screen.
Erwin is a recently appointed Associate Professor in single cell proteomics in disease biology at the Technical University of Denmark. His research focuses on normal and malignant hematopoiesis, and he has spent the last few years optimizing a single cell proteomics workflow to be used for deciphering cellular heterogeneity. He is also the head of the DTU Proteomics Core, a facility specialized in high sensitivity proteomics workflows.
The focus of our research is in the development of mass spectrometry based proteomics approaches to improve our understanding of biology on a molecular, cellular, and whole organism level. Presently, individuals in the laboratory are working on technology for 1) automating biochemical sample preparation methods for the analysis of protein mixtures; 2) methods for improving the systematic and quantitative sampling of peptides using tandem mass spectrometry; and 3) developing computational tools for the automated conversion of mass spectrometry data into biologically meaningful results. These technologies are currently being applied to improve our understanding of Alzheimer's disease and related dementias, the basic biology of aging, diabetes, and the assessment of general wellness.
I grew up in rural Michigan and during these formative years greatly enjoyed flyfishing and woodworking. Putting the latter interest to practical use, I constructed several riverboats (for fishing) while in high school and college. Chemistry interested me, especially Analytical Chemistry, as it offered an avenue to continue “building”. Not boats, but chemical instrumentation. To escape the cold I joined the Chemistry graduate program at the University of Florida and worked with Willard Harrison. Professor Harrison didn’t just guide my research, he taught me how to write, present, and think like a scientist. He was a gentleman in every sense of the word. Upon graduation in 2002, I moved to Charlottesville, Virginia to join the laboratory of Professor Don Hunt. At Virginia I met John Syka. Don and John both shared a passion for science that was as infectious as it was inspiring. Together we worked to develop electron transfer dissociation (ETD). ETD worked just as we had hoped and the dissociation technique is now commonly used for proteomics and has been commercially introduced by no fewer than four major instrument vendors. In 2005 I moved to Wisconsin to start my own program. And though we have been productive and impactful with ~ 200 published manuscripts, I am most proud to have produced nearly 20 Ph.D. scientists, and our academic family continues to grow.
Dr. Geiger is an associate professor at the Department of Human Molecular Genetics and Biochemistry at the Sackler Faculty of Medicine at Tel Aviv University. Geiger completed her BSc studies in life sciences at the Hebrew University of Jerusalem. She then continued and performed her M.Sc and Ph.D. studies in the same university studying cancer signaling under the supervision of Prof. Alexander Levitzki. For her post-doctoral training, in 2008 she moved to the laboratory of Prof. Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried, Germany. During her post-doc, Geiger specialized in mass spectrometry-based proteomics, developed techniques, and applied it to cancer-related questions. In 2011, she returned to Israel and opened her independent research group at Tel Aviv University, and in 2021 Geiger will move to the Weizmann Institute of Science to pursue clinical proteomic research.